Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMAG PHARMACEUTICALS, INC.AMAG · Entity 145305 | Chief Medical Officer | March 02, 2020 | March 04, 2020 |
| Aquestive Therapeutics, Inc.AQST · Entity 5276 | Director | June 23, 2026 | June 24, 2026 |
| DiaMedica Therapeutics Inc.DMAC · Entity 5813 | Chief Medical Officer | June 01, 2026 | June 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMAG PHARMACEUTICALS, INC.
Report date March 02, 2020 · Filed March 04, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 73,044 |
Reported balance
After 2020-03-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-03-02 · Tax withholding · Disposed 1,333 · Balance 73,044 F1: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 4,333 restricted stock units ("RSUs") on March 2, 2020. F2: Reporting person's total beneficial ownership has been adjusted to reflect that no shares were awarded pursuant to the performance-based RSU award granted on February 23, 2017. The reporting person had previously reported beneficial ownership of 7,500 shares pursuant to the RSU award, which represented the target number of shares that could have been delivered based on the achievement of certain relative total stockholder return targets over a three year performance period, which were not met, and which target share amount was previously reported on a Form 4 filed on February 27, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 4,333 restricted stock units ("RSUs") on March 2, 2020.
F2: Reporting person's total beneficial ownership has been adjusted to reflect that no shares were awarded pursuant to the performance-based RSU award granted on February 23, 2017. The reporting person had previously reported beneficial ownership of 7,500 shares pursuant to the RSU award, which represented the target number of shares that could have been delivered based on the achievement of certain relative total stockholder return targets over a three year performance period, which were not met, and which target share amount was previously reported on a Form 4 filed on February 27, 2017.
Aquestive Therapeutics, Inc.
Report date June 23, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-06-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-23 · Exercise / conversion · Acquired 25,000 · Balance 25,000 F1: This is a scheduled exercise from 10b5-1 trading plan. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was affected. Row 2 · 2026-06-23 · Sale · Disposed 25,000 · Balance 0 F2: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.71 · Expires 2032-06-22 | Direct | 0 |
Reported balance
After 2026-06-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-23 · Exercise / conversion · Disposed 25,000 · Balance 0 F1: This is a scheduled exercise from 10b5-1 trading plan. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was affected. F3: This option was granted on June 22, 2022 and is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: This is a scheduled exercise from 10b5-1 trading plan. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was affected.
F2: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4.
F3: This option was granted on June 22, 2022 and is fully vested.
DiaMedica Therapeutics Inc.
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.84 · Expires 2036-06-01 | Direct | 67,500 |
Reported balance
After 2026-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 67,500 · Balance 67,500 F1: Scheduled to vest with respect to 25% of the shares on the one-year anniversary of the grant date, with the remaining shares scheduled to vest in twelve equivalent quarterly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: Scheduled to vest with respect to 25% of the shares on the one-year anniversary of the grant date, with the remaining shares scheduled to vest in twelve equivalent quarterly installments.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 23, 2026 Filed Jun 24, 2026 15:11 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001214659-26-007677 · marketforms-73450.xml · derivative · entry 3 Krop Julie · CIK 0001643127 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2032-06-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise from 10b5-1 trading plan. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was affected. F3 · derivative.exercise_date: This option was granted on June 22, 2022 and is fully vested. Read SEC document |
| June 23, 2026 Filed Jun 24, 2026 15:11 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | SaleCommon Stock | 25,000 | $5.02 | $125,392.50 |
DisclosureSEC source: 0001214659-26-007677 · marketforms-73450.xml · nonDerivative · entry 2 Krop Julie · CIK 0001643127 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4. Read SEC document |
| June 23, 2026 Filed Jun 24, 2026 15:11 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 25,000 | $0.71 | $17,830.00 |
DisclosureSEC source: 0001214659-26-007677 · marketforms-73450.xml · nonDerivative · entry 1 Krop Julie · CIK 0001643127 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise from 10b5-1 trading plan. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was affected. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 15:43 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (Right to Purchase) · Derivative | 50,500 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001214659-26-007398 · marketforms-73384.xml · derivative · entry 1 Krop Julie · CIK 0001643127 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,500 Underlying: Common Stock · 50,500 shares Expires 2036-06-10 F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 10, 2027, subject to Dr. Krop's continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 21:22 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 67,500 | $0.00 Strike: $5.84 | $0.00 |
DisclosureSEC source: 0001643127-26-000002 · form4-06032026_090627.xml · derivative · entry 1 Krop Julie · CIK 0001643127 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,500 Underlying: Voting Common Shares · 67,500 shares Expires 2036-06-01 F1 · derivative.exercise_date: Scheduled to vest with respect to 25% of the shares on the one-year anniversary of the grant date, with the remaining shares scheduled to vest in twelve equivalent quarterly installments. Read SEC document |
| August 11, 2025 Filed Nov 3, 2025 21:32 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 450,000 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0001643127-25-000006 · form4-11032025_091158.xml · derivative · entry 1 Krop Julie · CIK 0001643127 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2035-08-10 F1 · derivative.exercise_date: 112,500 shares vest on the one-year anniversary of the grant date, and the remaining 337,500 shares vest in twelve equal, or as nearly equal as possible, quarterly installments commencing three months after the one-year anniversary of the grant date; provided, however, that the participant remains continuously employed by or provides services to the Company, or one of its Subsidiaries or Affiliates, through the applicable vesting date. Read SEC document |
| June 11, 2025 Filed Jun 12, 2025 17:59 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (Right to Purchase) · Derivative | 42,000 | $3.41 Strike: $3.41 | $143,220.00 |
DisclosureSEC source: 0001214659-25-009123 · marketforms-69482.xml · derivative · entry 1 Krop Julie · CIK 0001643127 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2035-06-11 F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 11, 2026, subject to Dr. Krop's continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 17:50 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (Right to Purchase) · Derivative | 38,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001214659-24-011218 · marketforms-66326.xml · derivative · entry 1 Krop Julie · CIK 0001643127 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2034-06-20 F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 20, 2025, subject to Dr. Krop's continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 16:28 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (Right to Purchase) · Derivative | 25,000 | $0.00 Strike: $2.02 | $0.00 |
DisclosureSEC source: 0001214659-23-008797 · marketforms-61961.xml · derivative · entry 1 Krop Julie · CIK 0001643127 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 21, 2024, subject to Dr. Krop's continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 20:22 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (Right to Purchase) · Derivative | 25,000 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001214659-22-008288 · marketforms-56517.xml · derivative · entry 1 Krop Julie · CIK 0001643127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-22 F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 22, 2023, subject to Dr. Krop's continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 22:50 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (Right to Purchase) · Derivative | 20,000 | $0.00 Strike: $4.04 | $0.00 |
DisclosureSEC source: 0001214659-21-006716 · marketforms-53149.xml · derivative · entry 1 Krop Julie · CIK 0001643127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-06-15 F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 15, 2022, subject to Dr. Krop's continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
| March 11, 2021 Filed Mar 15, 2021 21:10 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 28,500 | $0.00 Strike: $5.30 | $0.00 |
DisclosureSEC source: 0001214659-21-003154 · marketforms-51884.xml · derivative · entry 1 Krop Julie · CIK 0001643127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,500 Underlying: Common Stock · 28,500 shares Expires 2031-03-11 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on March 11, 2022. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 17:48 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 1,333 | $7.75 | $10,330.75 |
DisclosureSEC source: 0001104659-20-029288 · a4.xml · nonDerivative · entry 1 Krop Julie · CIK 0001643127 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,044 F1 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 4,333 restricted stock units ("RSUs") on March 2, 2020. F2 · balance_after: Reporting person's total beneficial ownership has been adjusted to reflect that no shares were awarded pursuant to the performance-based RSU award granted on February 23, 2017. The reporting person had previously reported beneficial ownership of 7,500 shares pursuant to the RSU award, which represented the target number of shares that could have been delivered based on the achievement of certain relative total stockholder return targets over a three year performance period, which were not met, and which target share amount was previously reported on a Form 4 filed on February 27, 2017. Read SEC document |
| February 25, 2020 Filed Feb 25, 2020 16:46 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 1,155 | $8.84 | $10,210.20 |
DisclosureSEC source: 0000792977-20-000018 · wf-form4_158266714405265.xml · nonDerivative · entry 2 Krop Julie · CIK 0001643127 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,877 F3 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 3,333 restricted stock units on February 25, 2020. Read SEC document |
| February 23, 2020 Filed Feb 25, 2020 16:46 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 867 | $9.50 | $8,236.50 |
DisclosureSEC source: 0000792977-20-000018 · wf-form4_158266714405265.xml · nonDerivative · entry 1 Krop Julie · CIK 0001643127 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,032 F1 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 2,501 restricted stock units on February 23, 2020. F2 · balance_after: Reporting person's total beneficial ownership reflects the purchase of 2,500 shares through an Employee Stock Purchase Plan on November 30, 2019. Read SEC document |
| May 28, 2019 Filed May 29, 2019 16:27 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | PurchaseCommon Stock | 10,000 | $9.91 | $99,100.00 |
DisclosureSEC source: 0000792977-19-000113 · wf-form4_155916164243275.xml · nonDerivative · entry 1 Krop Julie · CIK 0001643127 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,399 F1 · price: The shares purchased on this date were purchased in multiple transactions. The actual purchase prices range from $9.85 to $9.96, inclusive. Upon request by the Securities and Exchange Commission, the issuer, or any security holder of the issuer, the reporting person will provide full information regarding the number of shares purchased at each price. Read SEC document |
| March 02, 2019 Filed Mar 5, 2019 18:09 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 1,247 | $14.76 | $18,405.72 |
DisclosureSEC source: 0000792977-19-000047 · wf-form4_155182733771361.xml · nonDerivative · entry 2 Krop Julie · CIK 0001643127 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,399 F2 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 4,332 restricted stock units on March 2, 2019. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 18:09 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 960 | $14.76 | $14,169.60 |
DisclosureSEC source: 0000792977-19-000047 · wf-form4_155182733771361.xml · nonDerivative · entry 1 Krop Julie · CIK 0001643127 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,646 F1 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 3,001 restricted stock units on March 1, 2019. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 18:30 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantStock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $15.51 | Not disclosed |
DisclosureSEC source: 0000792977-19-000031 · wf-form4_155131021117253.xml · derivative · entry 3 Krop Julie · CIK 0001643127 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-02-25 F3 · price: Not applicable. F5 · derivative.exercise_date: Grant of stock option pursuant to the Plan. This option will vest and become exercisable over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 18:30 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantCommon Stock | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000792977-19-000031 · wf-form4_155131021117253.xml · nonDerivative · entry 2 Krop Julie · CIK 0001643127 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,606 F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). F4 · shares: These shares of Common Stock are issuable pursuant to a performance-based RSU grant under a long-term incentive program under the Plan and will be earned, if at all, based on achievement of certain relative total stockholder return targets over the three year performance period ending February 25, 2022 subject to continuation of a business relationship with the grantee through the conclusion of the performance period. The number above represents the target number of shares that may be delivered pursuant to the award ("Target Award"); however, the amount that vests could range from zero to 150% of the Target Award. F3 · price: Not applicable. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 18:30 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantCommon Stock | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000792977-19-000031 · wf-form4_155131021117253.xml · nonDerivative · entry 1 Krop Julie · CIK 0001643127 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,606 F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). F2 · shares: These shares of Common Stock are issuable pursuant to a grant of RSUs pursuant to the Issuer's Fourth Amended & Restated 2007 Equity Incentive Plan, as amended (the "Plan") that will vest in three equal annual installments with the first installment vesting on February 25, 2020. F3 · price: Not applicable. Read SEC document |
| February 23, 2019 Filed Feb 26, 2019 17:48 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 869 | $15.51 | $13,478.19 |
DisclosureSEC source: 0000792977-19-000024 · wf-form4_155122127416444.xml · nonDerivative · entry 1 Krop Julie · CIK 0001643127 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,606 F1 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 2,500 restricted stock units on February 23, 2019. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 16:03 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 2,161 | $19.85 | $42,895.85 |
DisclosureSEC source: 0000792977-18-000047 · wf-form4_153064816548719.xml · nonDerivative · entry 1 Krop Julie · CIK 0001643127 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,475 F1 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 7,335 restricted stock units ("RSUs") on June 1, 2018. Due to the black-out policies implemented by AMAG Pharmaceuticals, Inc. (the "Issuer"), the shares of the Issuer's Common Stock underlying such vested RSUs were not delivered to the reporting person until July 2, 2018, at which time 2,161 shares were withheld to satisfy the reporting person's applicable tax obligations. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 19:23 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantStock Option (Right to Buy) · Derivative | 22,000 | Not disclosed Strike: $21.00 | Not disclosed |
DisclosureSEC source: 0001179110-18-003694 · edgar.xml · derivative · entry 4 Krop Julie · CIK 0001643127 · EVP, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2028-03-02 F3 · price: Not applicable. F6 · derivative.exercise_date: Grant of stock option pursuant to the Plan. This option will vest and become exercisable over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 19:23 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 1,700 | $21.00 | $35,700.00 |
DisclosureSEC source: 0001179110-18-003694 · edgar.xml · nonDerivative · entry 3 Krop Julie · CIK 0001643127 · EVP, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,636 F5 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 2,499 RSUs on February 23, 2018 and 3,000 RSUs on March 1, 2018. Due to the black-out policies implemented by the Issuer, the shares of the Issuer's Common Stock underlying such vested RSUs were not delivered to the reporting person until March 2, 2018, at which time an aggregate of 1,700 shares were withheld to satisfy the reporting person's applicable tax obligations. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 19:23 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantCommon Stock | 12,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-18-003694 · edgar.xml · nonDerivative · entry 2 Krop Julie · CIK 0001643127 · EVP, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,336 F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). F4 · shares: These shares of Common Stock are issuable pursuant to a performance-based RSU grant under a long-term incentive program under the Plan and will be earned, if at all, based on achievement of certain relative total stockholder return targets over the three year performance period ending March 1, 2021 subject to continuation of a business relationship with the grantee through the conclusion of the performance period. The number above represents the target number of shares that may be delivered pursuant to the award ("Target Award"); however, the amount that vests could range from zero to 150% of the Target Award. F3 · price: Not applicable. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 19:23 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantCommon Stock | 13,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-18-003694 · edgar.xml · nonDerivative · entry 1 Krop Julie · CIK 0001643127 · EVP, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,336 F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). F2 · shares: These shares of Common Stock are issuable pursuant to a grant of RSUs pursuant to the Issuer's Fourth Amended and Restated 2007 Equity Incentive Plan (as amended the "Plan") and will vest in three equal annual installments with the first installment vesting on March 2, 2019. F3 · price: Not applicable. Read SEC document |
| July 13, 2017 Filed Jul 14, 2017 16:26 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | SaleCommon Stock | 4,938 | $20.00 | $98,760.00 |
DisclosureSEC source: 0001179110-17-010382 · edgar.xml · nonDerivative · entry 1 Krop Julie · CIK 0001643127 · SVP Clinical & Regulatory, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,336 F1 · shares: The reported transaction on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 16, 2016. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 08:42 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 2,395 | $17.90 | $42,870.50 |
DisclosureSEC source: 0001179110-17-008492 · edgar.xml · nonDerivative · entry 2 Krop Julie · CIK 0001643127 · SVP Clinical & Regulatory, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,274 F3 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 7,333 restricted stock units on June 1, 2017. Read SEC document |
| May 01, 2017 Filed May 2, 2017 17:07 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | SaleCommon Stock | 1,891 | $24.45 | $46,234.95 |
DisclosureSEC source: 0001179110-17-006402 · edgar.xml · nonDerivative · entry 1 Krop Julie · CIK 0001643127 · SVP Clinical & Regulatory, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,777 F1 · shares: The reported transaction on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 16, 2016. Read SEC document |
| March 01, 2017 Filed Jun 5, 2017 08:42 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 1,108 | $22.85 | $25,317.80 |
DisclosureSEC source: 0001179110-17-008492 · edgar.xml · nonDerivative · entry 1 Krop Julie · CIK 0001643127 · SVP Clinical & Regulatory, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,669 F1 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 2,999 restricted stock units on March 1, 2017. F2 · balance_after: The Reporting Person's Form 4 filed on May 2, 2017 did not take into account the shares withheld on March 1, 2017, and therefore the amount reported in Column 5 on such Form 4 was overstated by 1,108 shares. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 18:58 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $23.75 | Not disclosed |
DisclosureSEC source: 0001179110-17-003320 · edgar.xml · derivative · entry 3 Krop Julie · CIK 0001643127 · SVP Clinical & Regulatory, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-02-23 F3 · price: Not applicable. F5 · derivative.exercise_date: Grant of stock option pursuant to the Plan. This option will vest and become exercisable over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 18:58 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantCommon Stock | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-003320 · edgar.xml · nonDerivative · entry 2 Krop Julie · CIK 0001643127 · SVP Clinical & Regulatory, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,668 F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). F4 · shares: These shares of Common Stock are issuable pursuant to a performance-based RSU grant under a long-term incentive program under the Plan and will be earned, if at all, based on achievement of certain relative total stockholder return targets over the three year performance period ending December 31, 2019, subject to continuation of a business relationship with the grantee through the conclusion of the performance period. The number above represents the target number of shares that may be delivered pursuant to the award ("Target Award"); however, the amount that vests could range from zero to 150% of the Target Award. F3 · price: Not applicable. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 18:58 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantCommon Stock | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-003320 · edgar.xml · nonDerivative · entry 1 Krop Julie · CIK 0001643127 · SVP Clinical & Regulatory, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,168 F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). F2 · shares: These shares of Common Stock are issuable pursuant to a grant of RSUs pursuant to the Issuer's Third Amended and Restated 2007 Equity Incentive Plan (as amended the "Plan") and will vest in three equal annual installments with the first installment vesting on February 23, 2018. F3 · price: Not applicable. Read SEC document |
| October 20, 2016 Filed Oct 20, 2016 16:07 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | SaleCommon Stock | 4,938 | $24.80 | $122,462.40 |
DisclosureSEC source: 0001179110-16-030835 · edgar.xml · nonDerivative · entry 1 Krop Julie · CIK 0001643127 · SVP Clinical & Regulatory, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,668 F1 · shares: The reported transaction on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 16, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.